A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Cancer
Non Hodgkin Lymphoma (NHL)
Diffuse Large B-Cell Lymphoma (DLBCL)
Lymphoma

Results
Download

Study results

LPS YO42610 GLOSHINE Final Results July 2025 English (PDF, 0.3 MB)

LPS YO42610 GLOSHINE Final Results July 2025 Chinese (PDF, 0.5 MB)

What is Clinical Research?

In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.

A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Study results

LPS YO42610 GLOSHINE Final Results July 2025 English (PDF, 0.3 MB)

LPS YO42610 GLOSHINE Final Results July 2025 Chinese (PDF, 0.5 MB)

What is Clinical Research?

For the latest version of this information please go to www.forpatients.roche.com

External Site

Directly contact Roche for questions

Contact the hospital directly

You are about to leave ForPatients

Thank you

Request a call back

Find participating medical centers and current study status in each of them

A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

For the latest version of this information please go to www.forpatients.roche.com